Ignacio Durán

16.9k total citations · 2 hit papers
206 papers, 4.8k citations indexed

About

Ignacio Durán is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ignacio Durán has authored 206 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 93 papers in Surgery and 84 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ignacio Durán's work include Bladder and Urothelial Cancer Treatments (65 papers), Urinary and Genital Oncology Studies (41 papers) and Renal cell carcinoma treatment (40 papers). Ignacio Durán is often cited by papers focused on Bladder and Urothelial Cancer Treatments (65 papers), Urinary and Genital Oncology Studies (41 papers) and Renal cell carcinoma treatment (40 papers). Ignacio Durán collaborates with scholars based in Spain, United States and United Kingdom. Ignacio Durán's co-authors include Daniel Castellano, Yohann Loriot, Carmen Garrigós, Saman Maleki Vareki, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Chunzhang Wu, Guru Sonpavde and Christof Vulsteke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ignacio Durán

198 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2021 670 citations Thomas Powles, Yohann Loriot et al. profile →
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

2023 84 citations Thomas Powles, Yohann Loriot et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ignacio Durán Spain	37	2.3k	1.6k	1.5k	1.4k	656	206	4.8k
Benjamin Tan United States	33	2.9k 1.2×	1.6k 1.0×	829 0.6×	1.9k 1.4×	434 0.7×	163	5.0k
John F. Gibbs United States	39	2.1k 0.9×	1.9k 1.2×	705 0.5×	1.6k 1.1×	829 1.3×	150	4.7k
Umberto Basso Italy	35	2.1k 0.9×	775 0.5×	1.0k 0.7×	1.7k 1.2×	372 0.6×	236	4.7k
Young Suk Park South Korea	41	4.0k 1.7×	1.9k 1.2×	1.3k 0.9×	2.3k 1.6×	575 0.9×	227	6.3k
Lori A. Erickson United States	40	2.3k 1.0×	1.1k 0.7×	1.5k 1.0×	587 0.4×	992 1.5×	185	5.5k
Jorge Barriuso United Kingdom	34	2.4k 1.0×	1.1k 0.7×	979 0.7×	908 0.7×	859 1.3×	137	4.0k
Tomoyuki Yokose Japan	43	2.6k 1.1×	1.1k 0.7×	1.2k 0.8×	3.3k 2.4×	905 1.4×	272	6.6k
Alyssa M. Krasinskas United States	45	2.6k 1.1×	2.9k 1.8×	826 0.6×	1.7k 1.2×	1.8k 2.7×	170	6.3k
Tatsuro Okamoto Japan	40	2.3k 1.0×	578 0.4×	1.3k 0.8×	2.1k 1.5×	377 0.6×	215	4.9k
Shinichiro Miyoshi Japan	41	1.4k 0.6×	2.0k 1.2×	1.7k 1.1×	2.4k 1.8×	607 0.9×	290	6.3k

Countries citing papers authored by Ignacio Durán

Since Specialization

Citations

This map shows the geographic impact of Ignacio Durán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Durán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Durán more than expected).

Fields of papers citing papers by Ignacio Durán

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Durán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Durán. The network helps show where Ignacio Durán may publish in the future.

Co-authorship network of co-authors of Ignacio Durán

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Durán. A scholar is included among the top collaborators of Ignacio Durán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Durán. Ignacio Durán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Linares, Estefanía, I. Rivero Belenchón, Gemma Sancho, et al.. (2024). PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.. Journal of Clinical Oncology. 42(23_suppl). 192–192.

Milagro, Nuria Laínez, et al.. (2024). EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern Spain. SHILAP Revista de lepidopterología. 6. 100063–100063.

Heijden, Michiel Simon Van Der, Shilpa Gupta, Jens Bedke, et al.. (2024). Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.. Journal of Clinical Oncology. 42(16_suppl). 4563–4563. 3 indexed citations

Reig, Òscar, Laurence Crouzet, Andrea Necchi, et al.. (2024). 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1. Annals of Oncology. 35. S515–S516. 3 indexed citations

Puente, Javier, D. Castellano Gauna, Ignacio Durán, et al.. (2024). Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & Translational Oncology. 26(7). 1639–1646.

Sternberg, Cora N., Yohann Loriot, Ernest Choy, et al.. (2023). Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).. Journal of Clinical Oncology. 41(16_suppl). 4569–4569. 1 indexed citations

Baños, J.L. Gutiérrez, et al.. (2023). Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience. Clinical & Translational Oncology. 26(2). 549–553. 3 indexed citations

Climent, Miguel Ángel, Albert Font, Ignacio Durán, et al.. (2022). A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. European Journal of Cancer. 175. 110–119. 9 indexed citations

Garrigós, Carmen, Javier Puente, B. Mellado González, et al.. (2022). Single-Nucleotide Polymorphism Associations with Efficacy and Toxicity in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel. Pharmacogenomics. 23(11). 627–638. 1 indexed citations

10.

Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2020). 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Annals of Oncology. 31. S1319–S1319. 3 indexed citations

11.

Khalid, Sidra, Christopher M. Booth, Ignacio Durán, et al.. (2020). Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. European Urology Open Science. 21. 61–68. 2 indexed citations

12.

Rr, Martin, et al.. (2019). Phase transitions in tumor growth VII: The effect of periodic glucose pulses and privations in a cancer model. IRIS Research product catalog (Sapienza University of Rome). 6(1). 3 indexed citations

13.

López, R.A. Medina, et al.. (2018). Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer. Clinical & Translational Oncology. 21(6). 796–804. 6 indexed citations

14.

Durán, Ignacio, et al.. (2018). Glucose starvation as cancer treatment: Thermodynamic point of view. 5(3). 3 indexed citations

15.

Ashcroft, John, et al.. (2018). Healthcare resource utilisation associated with skeletal‐related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study. European Journal Of Haematology. 100(5). 479–487. 8 indexed citations

16.

Rodríguez-Moreno, Juan Francisco, María Apellániz-Ruiz, Juan María Roldán‐Romero, et al.. (2017). Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation. Journal of the National Comprehensive Cancer Network. 15(11). 1310–1315. 15 indexed citations

17.

Garrigós, Carmen, Ana Salinas, R.A. Medina López, et al.. (2017). Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. Oncotarget. 8(63). 106551–106564. 17 indexed citations

18.

Vera-Badillo, Francisco, Esther Conde, & Ignacio Durán. (2012). Chromophobe renal cell carcinoma: A review of an uncommon entity. International Journal of Urology. 19(10). 894–900. 76 indexed citations

19.

Maroto, Pablo, Gary R. Hudes, Janice P. Dutcher, et al.. (2011). Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus. Journal of Clinical Oncology. 29(13). 1750–1756. 83 indexed citations

20.

Hechmati, Guy, Amit Bahl, Diana Lüftner, et al.. (2011). PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY. Value in Health. 14(3). A168–A168. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact